{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T17:40:46Z","timestamp":1780422046157,"version":"3.54.1"},"reference-count":35,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study compared the safety and efficacy of osimertinib, a third\u2010generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), with those of other TKIs and its use alongside bevacizumab in patients with EGFR mutation\u2010positive advanced non\u2013small\u2010cell lung cancer. PubMed, Embase, Cochrane Library, Web of Science, China National Knowledge Infrastructure, Wanfang, and VIP databases were used to conduct extensive searches for relevant randomized controlled trials until January 30, 2024. Osimertinib monotherapy favored disease control rate, whereas the comparator treatment arm favored overall survival. Using subgroup analysis, the objective response rate and progression\u2010free survival (PFS) were significantly elevated by Osimertinib monotherapy compared with pemetrexed combined with carboplatin or cisplatin. The comparator treatment arm receiving gefitinib or erlotinib significantly favored progression\u2010free survival and overall survival compared with osimertinib monotherapy. In patients treated with osimertinib monotherapy, the incidence of all adverse events (AEs) decreased compared with comparator treatment arm. Anemia was the only AE associated with osimertinib monotherapy. Pemetrexed combined with carboplatin or cisplatin resulted in greater loss of appetite than osimertinib monotherapy. The most associated AE of osimertinib monotherapy was diarrhea, according to network analysis. Although its efficacy is not consistent with other EGFR TKIs, osimertinib was associated with a decrease in AEs in patients with EGFR mutation\u2010positive advanced non\u2013small\u2010cell lung cancer.<\/jats:p>","DOI":"10.1002\/cpdd.1483","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T06:04:51Z","timestamp":1731132291000},"page":"5-10","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Osimertinib Efficacy and Safety in Treating Epidermal Growth Factor Receptor Mutation\u2010Positive Advanced Non\u2013Small\u2010Cell Lung Cancer: A Meta\u2010Analysis"],"prefix":"10.1002","volume":"14","author":[{"given":"Mengmeng","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Thoracic Surgery Yangzhong People \u2019s Hospital  Zhenjiang City Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Yangzhong People \u2019s Hospital  Zhenjiang City Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Yangzhong People \u2019s Hospital  Zhenjiang City Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Yangzhong People \u2019s Hospital  Zhenjiang City Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkai","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery Yangzhong People \u2019s Hospital  Zhenjiang City Jiangsu Province China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01125-3"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw326"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1773"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-016-0268-z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0709662105"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70087-6"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000260"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-29364-8"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13623"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.004"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.6758"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.010"},{"key":"e_1_2_7_18_1","first-page":"1697","article-title":"Observation of clinical efficacy of osimertinib combined with bevacizumab in the first\u2010line treatment of EGFR sensitive mutation\u2010positive advanced non\u2010small cell lung cancer","volume":"21","author":"Feng X","year":"2022","journal-title":"J Clin Exp Med"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.006"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0611-3"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.04.012"},{"key":"e_1_2_7_22_1","first-page":"1340","article-title":"Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?","volume":"11","author":"Sznol M","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2935"},{"issue":"113","key":"e_1_2_7_24_1","first-page":"e1","article-title":"Disease control rate at 8 weeks predicts subsequent survival in platinum\u2010treated extensive stage small\u2010cell lung cancer: results from the southwest oncology group (SWOG) database","volume":"17","author":"Lara PN","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.21037\/pcm-20-72"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0337"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0573-8"},{"key":"e_1_2_7_28_1","first-page":"109","article-title":"Osimertinib in the treatment of non\u2010small\u2010cell lung cancer: design, development and place in therapy","volume":"8","author":"Santarpia M","year":"2017","journal-title":"Lung Cancer (Auckl)"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000146"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70364-X"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70393-X"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S363446"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241227677","article-title":"Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta\u2010analysis","volume":"16","author":"Zhou G","year":"2024","journal-title":"Ther Adv Med Onco"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.12.023"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S315385"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2020.02.019"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T11:35:19Z","timestamp":1736163319000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/cpdd.1483"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1483","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"2024-08-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-14","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}